Seyed Nooreddin Faraji

Dr. Seyed Nooreddin Faraji

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 May 2022 in BioMetals
Verified
Journal Article
Closed access
PDF file
SMSalman Mohammadi
Salman Mohammadi
MSMaryam Shafiee
Maryam Shafiee
SFSeyed Nooreddin Faraji
Seyed Nooreddin Faraji
MRMohsen Rezaeian
Mohsen Rezaeian
AGAli Ghaffarian-Bahraman
Ali Ghaffarian-Bahraman

19 February 2024 in Heliyon
Verified
Journal Article
Open access
EBEmad Behboudi
Emad Behboudi
SFSeyed Nooreddin Faraji
Seyed Nooreddin Faraji
GDGholamreza Daryabor
Gholamreza Daryabor
SHSeyed Mohammad Ali Hashemi
Seyed Mohammad Ali Hashemi
MAMaryam Asadi
Maryam Asadi
GHGholamreza Hatam
Gholamreza Hatam
A critical step in the drug design for SARS-CoV-2 is to discover its molecular targets. This study comprehensively reviewed the molecular mechanisms of SARS-CoV-2, exploring host cell tropism and interaction targets crucial for cell entry. The findings revealed that beyond ACE2 as the primary entry receptor, alternative receptors, co-receptors, and several proteases such as TMPRSS2, Furin, Cathepsin L, and ADAM play critical roles in virus entry and subsequent pathogenesis. Additionally, SARS-CoV-2 displays tropism in various human organs due to its diverse receptors. This review delves into the intricate details of receptors, host proteases, and the involvement of each organ. Polymorphisms in the ACE2 receptor and mutations in the spike or its RBD region contribute to the emergence of variants like Alpha, Beta, Gamma, Delta, and Omicron, impacting the pathogenicity of SARS-CoV-2. The challenge posed by mutations raises questions about the effectiveness of existing vaccines and drugs, necessitating consideration for updates in their formulations. In the urgency of these critical situations, repurposed drugs such as Camostat Mesylate and Nafamostat Mesylate emerge as viable pharmaceutical options. Numerous drugs are involved in inhibiting receptors and host factors crucial for SARS-CoV-2 entry, with most discussed in this review. In conclusion, this study may provide valuable insights to inform decisions in therapeutic approaches.

27 August 2016 in Applied Biochemistry and Biotechnology
Verified
Journal Article
Closed access
PDF file
MMMozafar Mohammadi
Mozafar Mohammadi
FNForoogh Nejatollahi
Foroogh Nejatollahi
YGYounes Ghasemi
Younes Ghasemi
SFSeyed Nooreddin Faraji
Seyed Nooreddin Faraji

1 April 2019 in International Immunopharmacology
Verified
Journal Article
Closed access
SFSeyed Nooreddin Faraji
Seyed Nooreddin Faraji
FNForoogh Nejatollahi
Foroogh Nejatollahi
ATAli-Mohammad Tamaddon
Ali-Mohammad Tamaddon
MMMozafar Mohammadi
Mozafar Mohammadi
AAAli Reza Aminsharifi
Ali Reza Aminsharifi

19 March 2025 in Journal of Integrative Bioinformatics
Verified
Journal Article
Open access
PDF file
ZMZahra Mosalanejad
Zahra Mosalanejad
SFSeyed Nooreddin Faraji
Seyed Nooreddin Faraji
MRMohammad Reza Rahbar
Mohammad Reza Rahbar
Ahmad GholamiAhmad Gholami
Ahmad Gholami
The glycoproteins 41 (gp41) of human immunodeficiency virus (HIV), located on the virus’s external surface, form six-helix bundles that facilitate viral entry into the host cell. Theta defensins, cyclic peptides, inhibit the formation of these bundles by binding to the GP41 CHR region. RC101, a synthetic analog of theta-defensin molecules, exhibits activity against various HIV subtypes. Molecular docking of the CHR and RC101 was done using MDockPeP and Hawdock server. The type of bonds and the essential amino acids in binding were identified using AlphaFold3, CHIMERA, RING, and CYTOSCAPE. Mutable amino acids within the peptide were determined using the CUPSAT and Duet. Thirty-two new peptides were designed, and their interaction with the CHR of the gp41 was analyzed. The physicochemical properties, toxicity, allergenicity, and antigenicity of peptides were also investigated. Most of the designed peptides exhibited higher binding affinities to the target compared to RC101; notably, peptides 1 and 4 had the highest binding affinity and demonstrated a greater percentage of interactions with critical amino acids of CHR. Peptides A and E displayed the best physiochemical properties among designed peptides. The designed peptides may present a new generation of anti-HIV drugs, which may reduce the likelihood of drug resistance.

1 January 2017
Verified
Journal Article
Open access
SKShahdah Khosropanah
Shahdah Khosropanah
SFSeyed Nooreddin Faraji
Seyed Nooreddin Faraji
HHHamzeh Habibi
Hamzeh Habibi
MYMajid Yavarian
Majid Yavarian
RMRoohollah Mansoori
Roohollah Mansoori
SHSezaneh Haghpanah
Sezaneh Haghpanah
Many cardiovascular diseases may require lifelong anticoagulation therapy. Warfarin is the most prescribed medication in this regard with serious side effects in some patients. Several single nucleotide polymorphisms (SNPs) affecting cytochrome P450 system can impact on warfarin metabolism and dosing. 230 cardiovascular patients have participated in the study. The INR levels were 1.5 to 3.5 with a mean range of 2.8. The subjects were divided into two case and control groups. The rs2108622 SNP of the CYP4F2 gene and its effect on warfarin dose requirements in these patients was evaluated.The results of our study showed a correlation between age and warfarin dosage. The overall frequency of the CC and TT allele of rs2108622 was 53.1% and 18.6%. Daily average dose of warfarin in CC, CT and TT variants was 3.5 ± 1.6, 4.5 ± 2.1 and 5.3 ± 2.1 respectively. The daily warfarin dose in patients with CC allele was significantly lower than that for CT or TT. The patients with TT allele required a 1.8 mg/day higher dose of warfarin than that of CC.While there are many studies regarding relation of age and warfarin dose, however, there are contradictory results about pharmacogentic status and warfarin dose in different ethnics. Our study demonstrates that polymorphism in the CYP4F2 rs2108622 has a significant impact on the warfarin requirements in Iranian patients.